Sheffield Cancer Research Center, Academic Unit of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK.
Nat Rev Clin Oncol. 2011 Dec 20;9(2):76-8. doi: 10.1038/nrclinonc.2011.198.
Bone-targeting treatments have transformed the quality of life of patients with metastatic bone disease. 2011 saw the emergence of denosumab—a RANK ligand-specific antibody—as a more-effective alternative treatment to bisphosphonates and of data on the use of bone-targeting treatments to prevent metastasis from breast and prostate cancers.
骨靶向治疗改变了转移性骨病患者的生活质量。2011 年，出现了 denosumab——一种 RANK 配体特异性抗体——作为比双膦酸盐更有效的替代治疗药物，以及关于使用骨靶向治疗预防乳腺癌和前列腺癌转移的数据。
